Rafferty Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Rafferty Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.21M	Buy	39,876 +15,496	+64%	+$475K	﹤0.01%	732
2026 Q2	$847K	Sell	24,380 -12,873	-35%	-$380K	﹤0.01%	818
2026 Q1	$859K	Buy	37,253 +8,375	+29%	+$189K	﹤0.01%	808
2025 Q4	$581K	Sell	28,878 -5,483	-16%	-$114K	﹤0.01%	884
2025 Q3	$634K	Buy	34,361 +18,612	+118%	+$366K	﹤0.01%	870
2025 Q2	$343K	Sell	15,749 -1,660	-10%	-$34.5K	﹤0.01%	955
2025 Q1	$322K	Sell	17,409 -9,890	-36%	-$242K	﹤0.01%	946
2024 Q4	$727K	Buy	27,299 +17,763	+186%	+$510K	﹤0.01%	847
2024 Q3	$224K	Buy	+9,536	New	+$216K	﹤0.01%	1083

Other funds holding AVBP

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.26B AUM 34.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Rafferty Asset Management's AVBP Position: Q3 2026 in Review

Rafferty Asset Management increased its ArriVent BioPharma (AVBP) stake by 64% in Q3 2026, buying an estimated $475K and bringing the position to 39,876 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #732.

Rafferty Asset Management first reported a position in AVBP in Q3 2024 and has held it in 9 quarters since. 96 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

Rafferty Asset Management held 39,876 shares of ArriVent BioPharma worth $1.21M as of Q3 2026.
Rafferty Asset Management bought 15,496 ArriVent BioPharma shares in Q3 2026, an estimated $475K.
ArriVent BioPharma made up ﹤0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #732 holding.
Rafferty Asset Management first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 9 quarters since.
96 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.